# Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

> **NCT02867800** · PHASE1 · COMPLETED · sponsor: **Monica Bhatia** · enrollment: 24 (actual)

## Conditions studied

- Sickle Cell Disease
- Graft Versus Host Disease

## Interventions

- **DRUG:** Diphenhydramine
- **DRUG:** Acetaminophen
- **DRUG:** Methylprednisolone
- **DRUG:** Meperidine
- **DRUG:** Alemtuzumab
- **DRUG:** Thymoglobulin
- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **DRUG:** Thiotepa
- **DRUG:** Cyclosporine
- **DRUG:** Tacrolimus
- **DRUG:** Methotrexate
- **DRUG:** Abatacept
- **PROCEDURE:** Marrow infusion
- **DRUG:** Sirolimus
- **DRUG:** Mycophenolate Mofetil

## Key facts

- **NCT ID:** NCT02867800
- **Lead sponsor:** Monica Bhatia
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2021-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02867800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02867800, "Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02867800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*